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vs. 64.9 for Tlysis and 66.1 for medical therapy(each p < 0.05) and were less
often women, 20.0%, vs. 36.2% and 36.1 %, respectively, (each p < 0.05).
Time to presentation was significantly longer for medically treated pts: 13.8h
vs. 4.4h for Tlysis and 3.3h for 10 PTCA (each p < 0.001). Delay> 12 hours
was the reason cited most often for pts not treated with thrombolysis. In-
hospital mortality is shown. Recurrent MI was similar in the 3 groups, 4.2%.
Conclusions: 11) In 1994 in the U.S., reperfusion therapy was used in 71 % of
pts with ST elevation MI at these hospitals. (2) The potential underutilization
of l' PTCA in women deserves further study. (3) Early mortality was similar
for Tlysis and l' PTCA, but highest for medically treated pts, which supports
further expansion of reperfusion therapy in ST elevation MI (including use of
strategies to shorten patient time to presentation) and the need for improved
medical therapies for thrombolytic ineligible patients.
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Does a Less Restrictive Indication for Thrombolytic
Therapy Cause More Iatrogenic Complications in
Acute Myocardial Infarction?
Udo Burczyk, Jbrg Rustige. Rudolf Schiele, Armin Koch, Rainer Uebis.
Jochen Senges, ALKK-Study-Group. Herzzentrum Ludwigshafen, Department of
Cardiology, Germany
Purpose: In consideration of possible severe complications thrombolytic
agents are administered to only 30% of patients with acute myocardial in-
farction (AMI) admitted to coronary care units in Western Europe. "The 60-
Minutes Myocardial Infarction Project" therefore investigates the effect of a
higher lysis rate (LR) on the frequency of complications.
Methods: The multicenter nationwide study includes 154 hospitals in Ger-
many. During an 8-month period 4650 consecutive patients with proven
transmural AMI were enrolled and complications occurring within 48 hours
after admission were registered for clinical centers with a low and high LR
1~50% versus >50%).
Results:
clinical centers: all LR < 50% LR > 50%
complications (within 48 h): n ~ 4650 n = 2768 n ~ 1882
death 8.0% 8.3% 7.5%
hemorrhagic stroke 0.4% 0.5% 0.2%
ventricular rupture 0.4% 0.4% 0.4%
moderate bleeding 2.4% 1.8% 3,3%
allergic reaction 0.8% 0.5% 1.3%
Christopher Granger. Harvey White. Maarten Simoons, Douglas Weaver, Joel Gore,
Phil Aylward. Gabriel Barbash. Kerry Lee. Robert Califf. GUSTO Investigators.
Duke University Medical Center; Durham, NC
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1755-51 Risk Factors for Stroke Following Thrombolytic
Therapy: Case-Control Study from the GUSTO Trial
In order to determine risk factors for stroke beyond the standard known fac-
tors of age. presenting blood pressure, weight. sex, and history of hyper-
tension which were collected on all patients in the GUSTO Trial. additional
data were collected for the 592 patients suffering stroke as well as 548 age-
matched controls. Odds ratios 195% el) were as follows:
For hemorrhagic stroke
7.6129-201
2.8 (1.1--6.61
3.4 (1.2-10)
0.96 (0.41-22)
1.8 (0.40-7.9)
1.6 (091-2.9)
1.3 (0.88-1.8)
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For any stroke
3.9 (1.4-11)
4.0 (2.0-8.1)
2.2 (0.76--B.3)
30 (1.8-50)
2.7 (0.88-8.3)
15 (0.97-25)
1.5(1.1-20)
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Facial or head trauma within 2 wks
History of stroke
Dementia
Atrial fibrillation
Warfarin use
Nonsteroidal anti-inflam matory use
Calcium blocker use
Beta blocker use
Both groups were similar in age, sex and coexisting diseases.
Conclusions: 1. 48-hour mortality was lower in clinical centers with a higher
LR. 2. Severe complications showed no significant difference. 3. Minor com-
plications were significantly more frequent in clinical centers with a higher
LR. 4. These results support a less restrictive indication for thrombolytic ther-
apy in AMI based on individual benefit-risk evaluation.
David J. Moliterno. Christopher Granger, Robert M. Califf. John M. Elliott.
Amanda Stebbins, Eric J. Topol, GUSTO Investigators. The Cleveland Clinic
Foundation. Cleveland, OH
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Previous studies of thrombolysis in acute myocardial infarction (AMI) have
noted lower efficacy in heavy patients and a higher incidence of bleeding
complications among lighter patients. In the GUSTO trial of 41 ,021 patients
receiving either streptokinase, a weight-adjusted dose of t-PA. or combina-
tion therapy for AMI, we prospectively collected data on patient weight and
postulated prognostic value based on this variable. Patients with increased
body mass were hypothesized to have reduced thrombolytic efficacy. Sur-
vival, along with moderate and severe bleeding complications, were there-
fore analyzed according to weight subgroups separated into deciles. Para-
doxically, inverse relationships between patient body weight and both bleed-
ing and mortality were demonstrated regardless of thrombolytic treatment
strategy. Moreover, in a multivariable model of predictors of mortality, pa-
tient body weight added significant independent prognostic information (X 2
= 19, P < 0.0001). In conclusion, an inverse relationship to mortality was
present throughout the weight range of patients. In contrast to previous ob-
servations, heavy weight patients actually have an improved prognosis.
1755-31 Improved Prognosis for Heavy Weight Patients
Receiving Thrombolysis in Acute Myocardial
Infarction - Bigger is Better: Results from GUSTO
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These findings suggest that recent facial or head trauma is a strong risk
factor for hemorrhagic stroke following thrombolytic therapy, and therefore
should generally be considered to be a contraindication to thrombolytic
therapy. History of stroke predisposes to both any stroke and hemorrhagic
stroke, and dementia appears to predispose to hemorrhagic stroke.
1755-61 Neurosurgical Evacuation for Intracranial
Hemorrhage Associated with Improved Outcome in
GUSTO
Kenneth W. Mahaffey. Harvey D. White. Christopher B. Granger, Robert M. Califf,
Joel M. Gore. W. Douglas Weaver. Maarten L. Simoons. Gabriel!. Barbash,
Michael A. Sloan, Eric J. Topol, GUSTO Investigators. Duke University Medical
Center. Durham, NC
In order to evaluate the impact of neurosurgical evacuation of intracranial
hemorrhage IICH) following thrombolytic therapy for acute myocardial infarc-
tion, we analyzed the 268 patients with ICH in the GUSTO Trial. In-hospital
mortality was 60% with only 13% of patients discharged with minor or no
disability. Of the 268 patients, 47 had neurosurgical intervention with the fol-
lowing results:
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For all patients with ICH, surgical evacuation was associated with a higher
likelihood of survival without disability (odds ratio 2.1, 95% CI 0.95-4.7). The
prognosis for patients with both SOH and parenchymal hemorrhage was very
poor regardless of treatment strategy. Although the differences in outcome
may be due in part to selection of patients for operation with lower mortality
risk, physicians caring for patients with suspected intracranial hemorrhage
following thrombolytic therapy should consider early neurosurgical consul-
tation and intervention to potentially decrease patient disability and improve
survival.
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1756-1 I Non Surgical Septum Reduction: A New Treatment for
Hypertrophic Obstructive Cardiomyopathy (HOCM)
U. Sigwart, P. Buszman, C. Knight, R. Vecht, R. Sulton, D. Gibson. Royal Brompton
Hospital, London, UK.
In patients with HOCM and marked intraventricular gradients resistant to
conventional drug treatment with beta blockers and/or Verapamil surgical
resection of the muscular septal bulge has been advocated. We have inves-
tigated a new catheter treatment in 5 patients with HOCM and significant
LV ouflow tract gradients. All patients were in class 3 NYHA with angina and
shortness of breath. Intraventricular gradients were measured with transep-
tally introduced Brockenbrough catheters in the LV inflow tract and arterial
catheters in the aortic root. All patients were studied at rest, during the Val-
salva manoeuvre, after nitrates and after Isoproterenol infusion. The mea-
surements were repeated during balloon occlusion of the first major septal
branch of the left anterior descending coronary artery. - In all patients the
resting intraventricular gradient was reduced to less than 20 mm/Hg and
provocative testing (nitrates and post extrasystolic potentation) failed to cre-
ate typical increments. The longest inflation time was 30 minutes. Three pa-
tients had Verapamil 0.5 mg injected through the angioplasty balloon which
resulted in a longer lasting gradient/reduction after deflation of the balloon.
- After informed consent. 2 patient had 3-5 ml of desiccated alcohol infused
through the inflated balloon catheter in order to devitalise the offending my-
ocardium. This resulted in a CK elevation up to 2,500 units and permanent
abolition of the intraventricular gradient accompanied by marked clinical im-
provement.
From these preliminary observations we conclude that non surgical sep-
tum ablation maybe a promising new technique for the treatment of HOCM.
Further studies are warranted.
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Long Term Results of Dual Chamber (DOD) Pacing in
114 Adult Patients with Obstructive Hypertrophic
Cardiomyopathy and Severe Drug-Refractory
Symptoms
Dorothea McAreavey, Lameh Fananapazir. NIH, Bethesda, MD
Several studies indicate that short term, dual chamber (DOD) pacing relieves
symptoms and reduces LV outflow tract (LVOT) obstruction in hypertrophic
cardiomyopathy(HCM). We evaluated the long term outcome of DOD pacing
in 114 adult patients (age, 47 ± 15 yrs) with obstructive HCM and symptoms
refractory to {J-blocker and verapamil therapy. Three sudden deaths occurred
during a follow up period of 34 ± 10 months, maximum, 52 months (98%
3-year survival rate). At the last follow up evaluation, the NYHA functional
class improved significantly(3.1 ± 0.54 versus 1.7 ± 0.72, p < 0.0001). Thirty-
seven patients (32%) became asymptomatic. Symptoms were improved in
a further 62 patients (54%). However, 12 patients (10%) continued to have
disabling symptoms for various reasons: 8 had persistent LVOT obstruction
(in 3 patients an aberrant papillary muscle contributed to the LVOT obstruc-
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tion and in 3 patients, rapid AV node conduction prevented RV pacing). 3
patients had severe LV diastolic dysfunction, and 1 patient had mitral valve
prolapse and regurgitation. Seven of the 12 patients underwent corrective
cardiac surgery, and two patients are being considered for cardiac transplan-
tation. At a follow up cardiac catheterization after 14 ± 8 months of pacing,
there were significant reductions in LVOT gradient (79 ± 45 mmHg versus
26 ± 31 mmHg, p < 0.0001) and LV systolic pressure (188 ± 44 mmHg ver-
sus 147 ± 32 mmHg, p < 0.0001) comparing baseline and follow up mea-
surements. Aortic pulse pressure increased (45 ± 17 mmHg versus 52 ± 14
mmHg, p < 0.01).
These results suggest that long term, DOD pacing relieves symptoms and
LVOT obstruction in most HCM patients who would otherwise have been
candidates for cardiac surgery.
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1756-31 Management and Prognosis of Asymptomatic
Patients with Hypertrophic Cardiomyopathy
Paolo Spirito, Pietro Bellone, Paolo Bruzzi, Carlo Vecchio. Divisione di Cardiologia,
Ospedali Galliera, Genoa, Italy
The clinical course of hypertrophic cardiomyopathy (HCM) is extremely het-
erogeneous; some patients develop severe symptoms of heart failure, some
die suddenly, but many remain asymptomatic throughout life. The progno-
sis of patients who are asymptomatic at initial examination, however, has
never been investigated systematically in a large study population. We ex-
amined the clinical course of all the patients with HCM who were evaluated
in our department during 10 years and were asymptomatic or had only mild
symptoms at initial examination. A total of 89 patients were followed for a
mean of 4.9 yrs (0.3-10.8). Of these 89 patients, 50 (56%) were not treated
with cardioactive medications during follow up. Annual mortality was 0.4%
(95% confidence interval 0.1-1.4); only 2 patients died, both showing pro-
gressive deterioration before death. Seventy-nine patients (89%) remained
clinically stable during follow up, 3 developed severe symptoms (functional
class III). and 5 did not progress to class III but experienced sustained ven-
tricular tachycardia or syncope. Echocardiographic assessment of cardiac
morphology showed that the 2 patients who died were in the small group
of 8 patients with particularly marked hypertrophy (2:30 mm) at initial ex-
amination. In conclusion, our results show that cardiac mortality is low in
patients with HCM who are asymptomatic or have only mild symptoms, and
that clinical deterioration usually occurs gradually. In the absence of data
showing that therapy prevents cardiac death or delays disease progression
in HCM, our results suggest that treatment should be used only for allevia-
tion of symptoms.
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1756-41 Dual Chamber Pacing in Refractory Hypertrophic
Obstructive Cardiomyopathy: A Two-Center
European Experience in 34 Consecutive Patients
Nicolas Sadoul', Alistair K.B. Slade 2, Jean Philippe Simon 1, Richard
C. Saumarez 2, Bernard Dodinot 1, Etienne Allot 1, William J. McKenna 2.
1 Department of Cardiology, Nancy, France; 2 St. Georges Hospital Medical School,
London, UK
Dual chamber pacing with complete right ventricular capture has been re-
ported to improve symptoms in drug refractory hypertrophic obstructive car-
diomyopathy (HOCM). We report the joint experience of 34 consecutive im-
planted patients.
34 patients, (22 male, mean age 50 ± 18 yrs, range 16-79) with mean
symptom duration 7.5 yrs and refractory symptoms (angina: Class II n = 10,
III n = 12, dyspnoea: Class II n = 6, Class III n = 26, classe IV n = 1, syncope:
n = 13) were implanted after temporary dual chamber pacing had shown left
ventricular outflow tract gradient reduction of >30% as assessed by Doppler
Echocardiography.
After a mean follow-up of 10.2 ± 10.1 months (range 1-72). 33 patients
remained alive. Symptoms improved as follows. Syncope was eliminated
in all but 2 patients and 1 patient developed syncope after implant. Angina
improved in 14 but was unchanged in 4 patients and worsened in 4 and de-
veloped in 5. Dyspnoea was improved in 28/33 and unchanged in 5 patients.
Left ventricular outflow tract gradient decreased from 75 ± 29 (range = 36-
115) mmHg to 35 ± 27 (range 6-80) mmHg [p < 0.001 J. Patients who did not
improve were younger (mean age 36.6 yrs) and had a shorter follow-up.
Concfusion. Longer follow up after pacing for HCM sees re-emergence of
old and development of new symptoms in some patients despite continued
medical therapy.
